Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Core Insights - Artelo Biosciences, Inc. has announced a private placement for the purchase and sale of 3,188,407 shares of common stock and warrants to purchase up to 6,376,814 shares at a price of $3.45 per share, with the transaction expected to close around March 30, 2026 [1][2] Group 1: Financial Details - The gross proceeds from the offering are anticipated to be approximately $11.0 million before deducting fees and expenses [2] - If the warrants are fully exercised, the potential additional gross proceeds could reach approximately $20.4 million [2] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, and repayment of certain bridge debt [2] Group 3: Securities Offering - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state laws [3] - The company has agreed to file a resale registration statement covering the securities as part of a registration rights agreement with investors [3] Group 4: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing unmet needs in various medical conditions [5]